Terms: = Leukemia AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Clinical Outcome
13 results:
1. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Pastore F; Gittinger H; Raab S; Tschuri S; Ksienzyk B; Konstandin NP; Schneider S; Rothenberg-Thurley M; Horny HP; Werner M; Sauerland MC; Amler S; Görlich D; Berdel WE; Wörmann B; Braess J; Hiddemann W; Tischer J; Herold T; Metzeler KH; Spiekermann K
Br J Haematol; 2023 Sep; 202(6):1165-1177. PubMed ID: 37455345
[TBL] [Abstract] [Full Text] [Related]
2. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract] [Full Text] [Related]
3. Impact of ptpn11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Stasik S; Eckardt JN; Kramer M; Röllig C; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause S; Herbst R; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Rácil Z; Platzbecker U; Berdel WE; Mayer J; Serve H; Müller-Tidow C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM; Thiede C;
Blood Adv; 2021 Sep; 5(17):3279-3289. PubMed ID: 34459887
[TBL] [Abstract] [Full Text] [Related]
4. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
[TBL] [Abstract] [Full Text] [Related]
5. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract] [Full Text] [Related]
6. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract] [Full Text] [Related]
7. Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.
de Smith AJ; Ojha J; Francis SS; Sanders E; Endicott AA; Hansen HM; Smirnov I; Termuhlen AM; Walsh KM; Metayer C; Wiemels JL
Oncotarget; 2016 Nov; 7(45):72733-72745. PubMed ID: 27683039
[TBL] [Abstract] [Full Text] [Related]
8. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S
Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011
[TBL] [Abstract] [Full Text] [Related]
9. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia.
Cheng CL; Hou HA; Lee MC; Liu CY; Jhuang JY; Lai YJ; Lin CW; Chen HY; Liu FT; Chou WC; Chen CY; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Tien HF
Blood; 2013 Apr; 121(16):3172-80. PubMed ID: 23449638
[TBL] [Abstract] [Full Text] [Related]
10. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Balgobind BV; Hollink IH; Arentsen-Peters ST; Zimmermann M; Harbott J; Beverloo HB; von Bergh AR; Cloos J; Kaspers GJ; de Haas V; Zemanova Z; Stary J; Cayuela JM; Baruchel A; Creutzig U; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
Haematologica; 2011 Oct; 96(10):1478-87. PubMed ID: 21791472
[TBL] [Abstract] [Full Text] [Related]
11. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Pollard JA; Alonzo TA; Gerbing RB; Woods WG; Lange BJ; Sweetser DA; Radich JP; Bernstein ID; Meshinchi S
Blood; 2006 Oct; 108(8):2764-9. PubMed ID: 16809615
[TBL] [Abstract] [Full Text] [Related]
12. ptpn11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group.
Loh ML; Reynolds MG; Vattikuti S; Gerbing RB; Alonzo TA; Carlson E; Cheng JW; Lee CM; Lange BJ; Meshinchi S;
Leukemia; 2004 Nov; 18(11):1831-4. PubMed ID: 15385933
[TBL] [Abstract] [Full Text] [Related]
13. Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis.
Podestà M; Piaggio G; Sessarego M; Pitto A; Figari O; Soracco M; Carella AM; Dejana A; Rosti V; Fugazza G; Ravera G; Lerma E; Cazzola M; Bacigalupo A; Frassoni F
Exp Hematol; 2000 Feb; 28(2):210-5. PubMed ID: 10706077
[TBL] [Abstract] [Full Text] [Related]
